WEBINAR RECORDING AVAILABLE - WATCH ON DEMAND

Changing the paradigm for colorectal cancer: Clinical practice & drug development

Many ongoing studies aim to improve treatment and outcomes for early-stage colorectal cancer, including guiding adjuvant chemotherapy decisions and bringing targeted therapies and immunotherapies into the early-stage setting.

Join us for a webinar and panel discussion on the ways in which the paradigm for colorectal cancer care is changing, particularly in the context of the latest 2022 data from ESMO, ASCO, and ASCO GI.

We will hear from Dr. Scott Kopetz, Professor and Deputy Chair in the Department of Gastrointestinal Medical Oncology at MD Anderson and the principal investigator of several Phase 1, 2, and 3 clinical trials, including trials for patients with BRAF mutated colorectal cancer that led to new standards of care. He will be joined by Dr. Angel Rodriguez, Oncology Medical Director at Natera and previously Director of the Clinical Trial Office at Houston Methodist Cancer Center.

Our speakers will discuss:

Unmet needs in the management of patients with colorectal cancer
Trends in colorectal cancer screening, clinical management, and drug development
How ctDNA can be used in clinical practice to assess need for adjuvant chemotherapy
The role of ctDNA in accelerating drug development for early-stage disease

watch now

Scott Kopetz

Professor and Deputy Chair in the Department of Gastrointestinal Medical Oncology, MD Anderson

Dr. Scott Kopetz, MD, PhD, joined MD Anderson Cancer Center in 2006 and is Professor and Deputy Chair in the Department of Gastrointestinal Medical Oncology. Dr. Kopetz is board-certified in internal medicine and in medical oncology. He has authored over 350 peer-reviewed articles in respected scientific journals such as New England Journal of Medicine, Journal of Clinical Oncology, Lancet, Lancet Oncology, JAMA, Cancer Discovery, and Nature Medicine. He is the principal investigator of several Phase 1, 2, and 3 clinical trials, including trials for patients with BRAF mutated colorectal cancer that led to new standards of care. Dr. Kopetz graduated from Vanderbilt University where he earned his bachelor’s degree in biomedical engineering/electrical engineering. He received his medical degree from Johns Hopkins School of Medicine. Dr. Kopetz completed his residency training in internal medicine at Duke University Medical Center, followed by a medical oncology fellowship at MD Anderson Cancer Center. He subsequently obtained a Ph.D. at the University of Texas in patient oriented biological research/cancer biology with his thesis focused on mechanisms of chemotherapy resistance in colorectal cancer.

Angel Rodriguez

Oncology Medical Director, Natera

Dr. Angel Augusto Rodriguez, MD, is a board-certified medical oncologist who specializes in breast medical oncology and conducted clinical research with circulating tumor DNA. Before joining Natera, Dr. Rodriguez practiced at Austin Cancer Centers and Houston Methodist Cancer Center where he was Director of the Clinical Trials Office and the Triple Negative Breast Cancer Clinic. While at Houston Methodist he was principal investigator of clinical trials and conducted clinical research with circulating tumor DNA.

moderator

John Simmons

Global VP Biopharma, Natera

John Simmons, PhD currently leads oncology biopharma partnerships at Natera. Before joining Natera, John completed his postdoctoral fellowship at the National Cancer Institute (NCI) and served as Vice President of Translational Medicine at Personal Genome Diagnostics (PGDx). He received his PhD in Tumor Biology from Georgetown University.